JUPITER NEUROSCIENCES, INC. Gain (Loss) on Extinguishment of Debt
JUPITER NEUROSCIENCES, INC. (JUNS) reported Gain (Loss) on Extinguishment of Debt of $857.72 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-04-01
- JUPITER NEUROSCIENCES, INC. gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was -$94.14K.
- JUPITER NEUROSCIENCES, INC. gain (loss) on extinguishment of debt for the quarter ending 2024-09-30 was $0.00.
- JUPITER NEUROSCIENCES, INC. gain (loss) on extinguishment of debt for the quarter ending 2024-06-30 was $951.87K.
- JUPITER NEUROSCIENCES, INC. gain (loss) on extinguishment of debt for the quarter ending 2023-12-31 was $0.00.
- JUPITER NEUROSCIENCES, INC. gain (loss) on extinguishment of debt for fiscal 2024 was $857.72K.
- JUPITER NEUROSCIENCES, INC. gain (loss) on extinguishment of debt for fiscal 2023 was -$887.95K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$94.14K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$94.14K derived: sum of 2 quarters · filed 2026-04-01 | $857.72K derived: sum of 3 quarters · filed 2026-04-01 | $857.72K 10-K · filed 2026-04-01 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $951.87K derived: sum of 2 quarters · filed 2025-11-14 | $951.87K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $951.87K 10-Q · filed 2025-08-19 | $951.87K 10-Q · filed 2025-11-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$217.53K derived: sum of 2 quarters · filed 2025-03-28 | -$887.95K 10-K · filed 2025-03-28 | |
| 2023-09-30 | -$217.53K 10-Q · filed 2024-12-23 | -$887.95K 10-Q · filed 2024-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |